Page 107 - MBCA_FULL REPORT_FINAL_FOR_WEB
P. 107
23. Bergers, G. and D. Hanahan, Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer, 2008. 8(8): p.
592-603.
24. Bottsford-Miller, J.N., R.L. Coleman, and A.K. Sood, Resistance and escape from antiangiogenesis therapy:
clinical implications and future strategies. J Clin Oncol, 2012. 30(32): p. 4026-34.
25. Dogan, S., F. Andre, and M. Arnedos, Issues in clinical research for metastatic breast cancer. Curr Opin
Oncol, 2013. 25(6): p. 625-9.
26. Stead, M., et al., Strengthening clinical cancer research in the United Kingdom. Br J Cancer, 2011. 104(10): p.
1529-34.
27. Research, L.C., Ludwig Cancer Research bestows half a billion in new funding to six eminent U.S. research
institutions 2014.
28. Foundation, B.C.R., Founder’s Fund. 2014.
29. Visco, F., Breast Cancer Deadline 2020 3rd Annual Progress Report. 2014.
30. Howlader N, N.A., Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich
Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National
Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data
submission, posted to the SEER web site, April 2014, N.A. Howlader N, Krapcho M, Garshell J, Miller D, Altekruse
SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). Editor. 2014.
31. McCorkle, R., et al., Self-management: Enabling and empowering patients living with cancer as a chronic
illness. CA Cancer J Clin, 2011. 61(1): p. 50-62.
32. Karamouzis, M.V., G. Ioannidis, and G. Rigatos, Quality of life in metastatic breast cancer patients under
chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care (Engl), 2007.
16(5): p. 433-8.
33. Holland, J.C., History of psycho-oncology: overcoming attitudinal and conceptual barriers. Psychosom
Med, 2002. 64(2): p. 206-21.
34. Network, N.C.C. NCCN Distress Thermometer for Patients. National Comprehensive Cancer Network
website. 2014 August 11, 2014]; Available from: http://www.nccn.org/patients/resources/life_with_cancer/pdf/
nccn_distress_thermometer.pdf.
35. Adler, N.E., et al., Cancer Care for the Whole Patient, A.E.K. Page, Editor. 2007: Institute of Medicine, National
Academies.
36. Tatla, R., et al., A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic
breast cancer clinical trials in Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium. 2012,
Cancer Research San Antonio, TX. p. P2-12-07.
37. Office of Communications, D.o.D.I., Food and Drug Administration, Gudiance for Industry Patient-Reported
Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009, Food and Drug
Administration: FDA Website.
38. Levit, L., et al., Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. 2013,
National Academy of Science: Institute of Medicine, The National Academies.
39. Aranda, S., et al., Mapping the quality of life and unmet needs of urban women with metastatic breast
cancer. Eur J Cancer Care (Engl), 2005. 14(3): p. 211-22.
40. Caplette-Gingras, A. and J. Savard, Depression in women with metastatic breast cancer: a review of the
literature. Palliat Support Care, 2008. 6(4): p. 377-87.
41. Turner, J., et al., Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology, 2005.
14(5): p. 396-407.
42. Grabsch, B., et al., Psychological morbidity and quality of life in women with advanced breast cancer: a
cross-sectional survey. Palliat Support Care, 2006. 4(1): p. 47-56.
107
